We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+13.3%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.83B
AUM Growth
-$193M
Cap. Flow
-$2.01B
Cap. Flow %
-41.54%
Top 10 Hldgs %
42.39%
Holding
141
New
14
Increased
13
Reduced
19
Closed
37

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$95.6M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$71.9M
3
AMED
Amedisys
AMED
+$70M
4
PCVX icon
Vaxcyte
PCVX
+$27.5M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$24.7M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$94.9M
2
BIIB icon
Biogen
BIIB
+$88.1M
3
AERI
Aerie Pharmaceuticals
AERI
+$73.5M
4
LUNG icon
Pulmonx
LUNG
+$62M
5
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$55.5M

Sector Composition

Rank Sector Weight
1 Healthcare 56.42%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSTL icon
51
Castle Biosciences
CSTL
$737M
$6.41M 0.13%
+272,135
New +$6.31M
TOI icon
52
The Oncology Institute
TOI
$517M
$5.54M 0.11%
3,360,052
– –
FHTX icon
53
Foghorn Therapeutics
FHTX
$301M
$4.96M 0.1%
777,525
– –
CABA icon
54
Cabaletta Bio
CABA
$452M
$4.29M 0.09%
464,252
– –
AFIB
55
DELISTED
Acutus Medical Inc
AFIB
$3.05M 0.06%
2,651,667
– –
ANNX icon
56
Annexon
ANNX
$875M
$3.02M 0.06%
583,913
– –
ABEO icon
57
Abeona Therapeutics
ABEO
$350M
$2.68M 0.06%
+869,565
New +$3.25M
WGS icon
58
GeneDx Holdings
WGS
$1.8B
$2.65M 0.05%
304,523
-209,825
-41% -$4.62M
CALC icon
59
CalciMedica
CALC
$11.3M
$2.64M 0.05%
377,265
– –
NYXH
60
Nyxoah
NYXH
$143M
$2.27M 0.05%
455,262
– –
ROIVW
61
DELISTED
Roivant Sciences Ltd. Warrant
ROIVW
$1.94M 0.04%
1,000,000
– –
ORTX
62
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.17M 0.02%
316,171
-378,771
-55% -$1.67M
PEPG icon
63
PepGen
PEPG
$133M
$802K 0.02%
60,009
-685,284
-92% -$8.85M
ONCR
64
DELISTED
Oncorus, Inc.
ONCR
$642K 0.01%
2,536,186
-612,791
-19% -$348K
SIEN
65
DELISTED
Sientra, Inc.
SIEN
$544K 0.01%
+267,995
New +$926K
CMAXW
66
DELISTED
CareMax, Inc. Warrant
CMAXW
$351K 0.01%
672,000
– –
MDVL
67
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$251K 0.01%
16,733
– –
BFLY.WS
68
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
$191K ﹤0.01%
733,333
– –
TOIIW
69
The Oncology Institute Warrant
TOIIW
$138K ﹤0.01%
1,250,000
– –
QSIAW
70
DELISTED
Quantum-Si Inc Warrant
QSIAW
$83.3K ﹤0.01%
333,333
– –
NAMSW icon
71
NewAmsterdam Pharma Warrant
NAMSW
$87.4M
$80.6K ﹤0.01%
+92,787
New +$76.4K
PKBOW
72
DELISTED
Peak Bio, Inc. Warrant
PKBOW
$73.4K ﹤0.01%
362,500
– –
SLGCW
73
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$48K ﹤0.01%
120,000
– –
SNRHW
74
DELISTED
Senior Connect Acquisition Corp. I Warrant
SNRHW
$30.1K ﹤0.01%
500,000
– –
TLSIW icon
75
TriSalus Life Sciences Warrant
TLSIW
$25.5M
$25K ﹤0.01%
333,333
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2022 Portfolio in Review

As of Q4 2022, Deerfield Management held 141 positions worth $4.83B, down 3.8% from $5.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deerfield Management withdrew a net $2.01B in Q4 2022, closing 37 positions and reducing 19 holdings. Its most notable exit was Gilead Sciences, an estimated $94.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 53% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Amylyx Pharmaceuticals worth $99.5M.

  • Deerfield Management's largest Q4 2022 buy was Amylyx Pharmaceuticals: 2,693,000 shares worth $99.5M.
  • Deerfield Management added most to Amedisys in Q4 2022, an estimated $70M increase.
  • Deerfield Management's biggest Q4 2022 reduction was Silk Road Medical, Inc. Common Stock, cutting an estimated $55.5M.
  • Deerfield Management fully exited Gilead Sciences in Q4 2022, selling an estimated $94.9M.
  • Deerfield Management's ten largest holdings make up 42% of its $4.83B portfolio in Q4 2022.
  • Deerfield Management opened 14 new positions and closed 37 in Q4 2022.
  • Deerfield Management's portfolio value fell 3.8% quarter-over-quarter to $4.83B.

Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.